Department of Obstetrics and Gynaecology, Juan Ramon Jimenez Hospital, Huelva, Spain.
Department of Obstetrics and Gynaecology, Virgen de Valme University Hospital, Seville, Spain.
Eur J Contracept Reprod Health Care. 2022 Aug;27(4):341-344. doi: 10.1080/13625187.2022.2054982. Epub 2022 Apr 11.
Our main goal was to evaluate whether a treatment protocol based on the combination of mifepristone and misoprostol for second-trimester foetal loss was more effective than misoprostol monotherapy.
This was an observational, retrospective, cross-sectional two-centre study of women receiving treatment for second-trimester pregnancy loss. Patients were recruited in two centres that used different treatment protocols: combined mifepristone-misoprostol treatment or misoprostol monotherapy.
A total of 99 patients were included in the study: 41 in the mifepristone-misoprostol combined treatment group and 58 in the misoprostol monotherapy group. The combined treatment group had shorter times to expulsion and shorter hospitalisations, as well as higher rates of hospital discharge within 24 h and complete abortion within the first 6 h and 12 h. There were no differences regarding secondary effects and complication rates.
A combination of mifepristone and misoprostol appears to be a feasible option for the treatment of second-trimester pregnancy loss.
我们的主要目标是评估米非司酮联合米索前列醇用于中期妊娠流产的治疗方案是否优于米索前列醇单药治疗。
这是一项在两个中心进行的观察性、回顾性、横断面研究，纳入了接受中期妊娠流产治疗的女性。患者招募于两个使用不同治疗方案的中心：联合使用米非司酮-米索前列醇治疗或米索前列醇单药治疗。
共有 99 例患者纳入研究：米非司酮-米索前列醇联合治疗组 41 例，米索前列醇单药治疗组 58 例。联合治疗组的排出时间和住院时间更短，24 小时内出院率以及 6 小时和 12 小时内完全流产率更高。两组的次要作用和并发症发生率无差异。
米非司酮联合米索前列醇似乎是治疗中期妊娠流产的一种可行选择。
